Showing results (2841-2850 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 17, 2016
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignanciesKiyotaka Yoh, Toshihiko Doi, Hironobu Ohmatsu, et al.
Investigational New Drugs|June 21, 2015
Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugsEkaterina Schreiber-Brynzak, Erik Klapproth, Christine Unger, et al.
Investigational New Drugs|June 21, 2015
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumorsMatthew Zibelman, Yu-Ning Wong, Karthik Devarajan, et al.
Investigational New Drugs|June 19, 2015
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)B B Y Ma, B C Goh, W T Lim, et al.
Investigational New Drugs|October 20, 2019
Impact of L-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumorHeejung Chae, Min-Hee Ryu, Jungeun Ma, et al.
Investigational New Drugs|June 17, 2020
Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective studyShingo Nasu, Hidekazu Suzuki, Takayuki Shiroyama, et al.
Investigational New Drugs|March 17, 2018
Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutationMidori Tanaka, Hidenobu Ishii, Hayato Moribuchi, et al.
Investigational New Drugs|January 20, 2018
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosisHak-Min Lee, Eunmyong Lee, So-Young Yeo, et al.
Investigational New Drugs|January 20, 2018
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancerAndreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, et al.
Investigational New Drugs|March 25, 2018
A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancerAkihiro Tamiya, Masahiro Morimoto, Shoichi Fukuda, et al.
Pageof 372